NCT03956108View on ClinicalTrials.gov

Active Surveillance for Low-risk Prostate Cancer - Evaluation of the Efficacy of Minimally Invasive Active Surveillance

NACompletedINTERVENTIONAL

Enrollment

280

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

December 12, 2019

Study Completion Date

March 1, 2020

Conditions

Prostate Cancer

Interventions

DIAGNOSTIC_TEST

MRI+targeted biopsies+Stockholm3-test

MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.

DIAGNOSTIC_TEST

PSA + systematic biopsies

Systematic biopsies and PSA test

Trial Locations (1)

17177

Karolinska Institutet, Stockholm

All Listed Sponsors

lead

Karolinska Institutet

OTHER

NCT03956108 - Active Surveillance for Low-risk Prostate Cancer - Evaluation of the Efficacy of Minimally Invasive Active Surveillance | Biotech Hunter | Biotech Hunter